These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6971912)

  • 41. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox.
    Wu WB; Peng HC; Huang TF
    Thromb Haemost; 2001 Dec; 86(6):1501-11. PubMed ID: 11776320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura.
    Casonato A; Pontara E; Bertomoro A; Ossi E; Vincenti M; Girolami A; Borsatti A; Bertaglia G
    Am J Hematol; 1996 Jan; 51(1):7-11. PubMed ID: 8571941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
    Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib.
    Fujimura Y; Ikeda Y; Miura S; Yoshida E; Shima H; Nishida S; Suzuki M; Titani K; Taniuchi Y; Kawasaki T
    Thromb Haemost; 1995 Aug; 74(2):743-50. PubMed ID: 8585016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
    Gaucher C; de Romeuf C; Rauïs-Morret M; Corazza F; Fondu P; Mazurier C
    Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autosomal dominant von Willebrand disease type 2M.
    Hermans C; Batlle J
    Acta Haematol; 2009; 121(2-3):139-44. PubMed ID: 19506360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific inhibiting effects of Ilexonin A on von Willebrand factor-dependent platelet aggregation under high shear rate.
    Li M; Wu WK; Liu L; Liao FL; Shinohara Y; Handa S; Goto S
    Chin Med J (Engl); 2004 Feb; 117(2):241-6. PubMed ID: 14975210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies on the mechanism of ristocetin-induced platelet agglutination: binding of ristocetin to platelets.
    Jenkins CS; Clemetson KJ; Lüscher EF
    J Lab Clin Med; 1979 Feb; 93(2):220-31. PubMed ID: 311800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ristocetin-induced platelet agglutination stimulates GPIIb/IIIa-dependent calcium influx.
    Bertolino G; Noris P; Spedini P; Balduini CL
    Thromb Haemost; 1995 Apr; 73(4):689-92. PubMed ID: 7495080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proceedings: Two cases of von Willebrand's disease with specific inhibitors of ristocetin induced aggregation of normal platelets.
    Blombäck M; Egberg N
    Thromb Diath Haemorrh; 1975 Nov; 34(2):583. PubMed ID: 1081749
    [No Abstract]   [Full Text] [Related]  

  • 53. [von Willebrand's disease with an increased ristocetin-induced platelet aggregation and a qualitative abnormality of the factor VIII protein (author's transl)].
    Takahashi H; Oda E; Hattori A; Kobayashi I; Takahashi K; Sakuragawa N; Shibata A
    Rinsho Ketsueki; 1980 Apr; 21(4):544-54. PubMed ID: 6774131
    [No Abstract]   [Full Text] [Related]  

  • 54. Proceedings: Variations in quantitative ristocetin platelet aggregation (RPA) with time after platelet rich plasma (PRP) preparation: association with alteration in pH.
    Coller BS; Gralnick HR
    Thromb Diath Haemorrh; 1975 Nov; 34(2):581-2. PubMed ID: 809
    [No Abstract]   [Full Text] [Related]  

  • 55. Racial differences in ristocetin-induced platelet aggregation.
    Buchanan GR; Holtkamp CA; Levy EN
    Br J Haematol; 1981 Nov; 49(3):455-64. PubMed ID: 6975118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Platelet anomaly in an eosinophilic myelophroliferative syndrome].
    Wautier JL; Dupuy E; Michel H; Caen JP
    Nouv Presse Med; 1976 Mar; 5(11):704-6. PubMed ID: 1083506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ristocetin induces platelet aggregation: a morphological demonstration.
    Escolar G; Monteagudo J; Villamor N; Garrido M; Castillo R; Ordinas A
    Br J Haematol; 1988 Jul; 69(3):379-86. PubMed ID: 3136792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired von Willebrand's syndrome in the course of Waldenström's disease.
    Mazurier C; Parquet-Gernez A; Descamps J; Bauters F; Goudemand M
    Thromb Haemost; 1980 Dec; 44(3):115-8. PubMed ID: 6781094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cleavage of rhamnose from ristocetin A removes its ability to induce platelet aggregation.
    Bardsley B; Williams DH; Baglin TP
    Blood Coagul Fibrinolysis; 1998 Apr; 9(3):241-4. PubMed ID: 9663706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acquired von Willebrand syndrome in multiple myeloma.
    Djunic I; Elezovic I; Ilic V; Tomin D; Suvajdzic-Vukovic N; Bila J; Antic D; Vidovic A; Milosevic-Jovcic N
    Hematology; 2011 Jul; 16(4):209-12. PubMed ID: 21756536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.